Radioimmunoconjugates (RICs) are radionuclides conjugated to monoclonal antibodies. The goal of radioimmunotherapy is to target radiation to tumor tissue while limiting the toxicity to normal cells. Our goal is to make a significant contribution in making radioimmunotherapy a new standard cancer treatment.


KEY ACHIEVEMENTS
²²⁷Thorium-rituximab targets and inhibits growth of CD20 positive tumors, (Blood, 2007).


GROUP MEMBERS
Principal investigator: Jostein Dahle
PhD-students: Nasir Abbas, Erta Kalanxhi, Helen Heyerdahl and Ada Repetto
Senior Bio Engineer: Camilla Mollatt
Guest scientist: Vanja Hårsaker

Our projects are sponsored by the Norwegian Cancer Society, the Norwegian Research council, the Health Authorities of South Eastern Norway, Innovation Norway, Algeta ASA and Nordic Nanovector AS.